GBT Key Statistics, Chart & Performance
The current stock price of GBT is 68.49 USD. In the past month the price increased by 0.9%. In the past year, price increased by 131.39%.
GBT Latest News, Press Relases and Analysis
GBT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 25 | 417.40B | ||
| AMGN | AMGEN INC | 15.43 | 181.72B | ||
| GILD | GILEAD SCIENCES INC | 15.46 | 157.14B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.58 | 109.42B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.79 | 80.12B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 855.65 | 57.20B | ||
| INSM | INSMED INC | N/A | 42.01B | ||
| NTRA | NATERA INC | N/A | 31.65B | ||
| BIIB | BIOGEN INC | 10.47 | 25.70B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.99 | 21.48B | ||
| INCY | INCYTE CORP | 15.9 | 19.93B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.10B |
Related stock screener links
About GBT
Company Profile
Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. The company is headquartered in South San Francisco, California and currently employs 457 full-time employees. The company went IPO on 2015-08-12. The firm is focused on Oxbryta (voxelotor), which is the Food and Drug Administration (FDA) approved medicine that inhibits sickle hemoglobin (HbS) polymerization, the root cause of red blood cell sickling in sickle cell disease (SCD). The company is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in Phase III development to address pain crises associated with the disease, and GBT021601 (GBT601), the Company’s next-generation HbS polymerization inhibitor. The firm is focused on areas of the United States, Europe, the Gulf Cooperation Council (GCC), region of the Middle East, and Latin America.
Company Info
GLOBAL BLOOD THERAPEUTICS IN
181 Oyster Point Blvd
South San Francisco CALIFORNIA 94080 US
CEO: Ted W. Love
Employees: 457
Phone: 16507417700.0
GLOBAL BLOOD THERAPEUTICS IN / GBT FAQ
What does GLOBAL BLOOD THERAPEUTICS IN do?
Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. The company is headquartered in South San Francisco, California and currently employs 457 full-time employees. The company went IPO on 2015-08-12. The firm is focused on Oxbryta (voxelotor), which is the Food and Drug Administration (FDA) approved medicine that inhibits sickle hemoglobin (HbS) polymerization, the root cause of red blood cell sickling in sickle cell disease (SCD). The company is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in Phase III development to address pain crises associated with the disease, and GBT021601 (GBT601), the Company’s next-generation HbS polymerization inhibitor. The firm is focused on areas of the United States, Europe, the Gulf Cooperation Council (GCC), region of the Middle East, and Latin America.
Can you provide the latest stock price for GLOBAL BLOOD THERAPEUTICS IN?
The current stock price of GBT is 68.49 USD. The price increased by 0.01% in the last trading session.
Does GLOBAL BLOOD THERAPEUTICS IN pay dividends?
GBT does not pay a dividend.
What is the ChartMill technical and fundamental rating of GBT stock?
GBT has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What sector and industry does GLOBAL BLOOD THERAPEUTICS IN belong to?
GLOBAL BLOOD THERAPEUTICS IN (GBT) operates in the Health Care sector and the Biotechnology industry.
Can you provide the growth outlook for GLOBAL BLOOD THERAPEUTICS IN?
The Revenue of GLOBAL BLOOD THERAPEUTICS IN (GBT) is expected to grow by 47.16% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the upcoming earnings date for GLOBAL BLOOD THERAPEUTICS IN?
GLOBAL BLOOD THERAPEUTICS IN (GBT) will report earnings on 2022-11-03, after the market close.
GBT Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to GBT. When comparing the yearly performance of all stocks, GBT is one of the better performing stocks in the market, outperforming 99.73% of all stocks.
GBT Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to GBT. GBT scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
GBT Financial Highlights
Over the last trailing twelve months GBT reported a non-GAAP Earnings per Share(EPS) of -5.01. The EPS decreased by -16.51% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -137.3% | ||
| ROA | -37.05% | ||
| ROE | N/A | ||
| Debt/Equity | 4.92 |
GBT Forecast & Estimates
22 analysts have analysed GBT and the average price target is 67.97 USD. This implies a price decrease of -0.77% is expected in the next year compared to the current price of 68.49.
For the next year, analysts expect an EPS growth of 2.94% and a revenue growth 47.16% for GBT